Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non Operating Income (2021 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Other Non Operating Income for 5 consecutive years, with $113000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 93.04% year-over-year to $113000.0, compared with a TTM value of $2.0 million through Dec 2025, down 69.85%, and an annual FY2025 reading of $2.0 million, down 69.85% over the prior year.
  • Other Non Operating Income was $113000.0 for Q4 2025 at Agios Pharmaceuticals, up from $67000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $6.5 million in Q2 2021 and bottomed at $67000.0 in Q3 2025.
  • Average Other Non Operating Income over 5 years is $1.9 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Other Non Operating Income soared 37.81% in 2024, then tumbled 95.94% in 2025.
  • Year by year, Other Non Operating Income stood at $3.3 million in 2021, then tumbled by 58.48% to $1.4 million in 2022, then grew by 26.23% to $1.7 million in 2023, then fell by 5.25% to $1.6 million in 2024, then crashed by 93.04% to $113000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for AGIO at $113000.0 in Q4 2025, $67000.0 in Q3 2025, and $523000.0 in Q2 2025.